Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

Jojima, Teruo ; Tomotsune, Takanori ; Iijima, Toshie ; Akimoto, Kazumi ; Suzuki, Kunihiro ; Aso, Yoshimasa

Diabetology and metabolic syndrome, 2016-07, Vol.8 (1), p.45-45, Article 45 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível